Cambridge Investment Research Advisors
MDVL

Cambridge Investment Research Advisors’s MedAvail Holdings, Inc. Common Stock MDVL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MDVL Stock Details MDVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-462
Closed -$22K – 3251
2022
Q1 		$22K Buy
+462
New +$27.8K ﹤0.01% 3119

Other funds holding MDVL

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AWGLSCP
ABG-WTT Global Life Science Capital Partners Central, Hong Kong, Hong Kong $12.3M AUM 3.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
CI
Cigna Investments Bloomfield, Connecticut $773M AUM 44.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cambridge Investment Research Advisors's MDVL Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of MedAvail Holdings, Inc. Common Stock (MDVL) in Q2 2022, closing a stake of 462 shares — an estimated $22K sold.

Cambridge Investment Research Advisors first reported a position in MDVL in Q1 2022 and held it in 1 quarter. The position peaked at $22K in Q1 2022. 38 funds tracked by Wall St. Rank hold MDVL as of Q2 2022.

  • Cambridge Investment Research Advisors reported no remaining MedAvail Holdings, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 462 MedAvail Holdings, Inc. Common Stock shares in Q2 2022, an estimated $22K.
  • Cambridge Investment Research Advisors first reported a position in MedAvail Holdings, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's MedAvail Holdings, Inc. Common Stock position peaked at $22K in Q1 2022.
  • 38 funds tracked by Wall St. Rank held MedAvail Holdings, Inc. Common Stock as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.